New system aims to enhance accessibility and adoption of robotic magnetic navigation.
Stereotaxis (NYSE: STXS) has received its first order for GenesisX, the latest evolution of its robotic magnetic navigation (RMN) system for endovascular surgery. The CE-marked system is currently under FDA review, with commercial launch preparations underway.
Key Advancements in GenesisX
Compact Design – Smaller magnets and built-in magnetic shielding eliminate the need for external room modifications.
Ease of Installation – No structural anchoring required; operates on standard 120/230V outlets.
Optimized Workflow – A single fiber connection to an 80% smaller system cabinet, which fits under an operating table.
Enhanced Performance – Faster, more responsive, and lighter than previous models, maintaining high surgical precision.
Path to Full Commercialization
In 2025, Stereotaxis will focus on:
- Regulatory approvals for EP and vascular catheters compatible with GenesisX.
- Demonstrating real-world clinical performance.
- Expanding system compatibility with various X-ray platforms.
- Scaling manufacturing, installation, and commercial operations.
David Fischel, CEO of Stereotaxis, highlighted the significance:
“GenesisX will transform robotic accessibility in endovascular surgery, marking a key step toward broader adoption of RMN technology.”
With this milestone, Stereotaxis moves closer to revolutionizing robotic navigation in minimally invasive surgery.
Follow MEDWIRE.AI for the latest updates in robotic-assisted surgery and endovascular innovation.
